C.M. Bidwell & Associates’s Regenxbio RGNX Stock Holding History

C.M. Bidwell & Associates’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,960	Closed	-$231K	–	543
2022 Q1	$231K	Buy	6,960 +2,635	+61%	+$73.2K	0.15%	129
2021 Q4	$141K	Buy	+4,325	New	+$147K	0.09%	215
2019 Q3	–	Sell	-800	Closed	-$41K	–	473
2019 Q2	$41K	Sell	800 -535	-40%	-$26.7K	0.04%	258
2019 Q1	$77K	Buy	+1,335	New	+$66.1K	0.08%	205

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

C.M. Bidwell & Associates's RGNX Position: Q2 2022 in Review

C.M. Bidwell & Associates sold out of Regenxbio (RGNX) in Q2 2022, closing a stake of 6,960 shares — an estimated $231K sold.

C.M. Bidwell & Associates first reported a position in RGNX in Q1 2019 and held it in 4 quarters. The position peaked at $231K in Q1 2022. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2022.

C.M. Bidwell & Associates reported no remaining Regenxbio position as of Q2 2022 after selling out during the quarter.
C.M. Bidwell & Associates sold 6,960 Regenxbio shares in Q2 2022, an estimated $231K.
C.M. Bidwell & Associates first reported a position in Regenxbio in Q1 2019 and held it in 4 quarters.
C.M. Bidwell & Associates's Regenxbio position peaked at $231K in Q1 2022.
165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2022.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.